About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
All
2024
2023
2022
2021
2020
11
Dec
2021
10:11 E.S.T.
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Read more
18
Nov
2021
13:44 E.S.T.
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China
Read more
11
Nov
2021
17:19 E.S.T.
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
Read more
04
Nov
2021
14:51 E.S.T.
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021
Read more
03
Nov
2021
18:40 E.S.T.
Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01
Read more
28
Oct
2021
11:08 E.S.T.
Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT
Read more
19
Oct
2021
14:19 E.S.T.
Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021
Read more
12
Oct
2021
14:53 E.S.T.
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Read more
26
Aug
2021
14:38 E.S.T.
Cellectis Announces Participation in Five Investor Conferences
Read more
05
Aug
2021
14:43 E.S.T.
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021
Read more
Prev
9
10
11
12
13
Next